» Articles » PMID: 20484504

The Ubiquitin-proteasome System Plays an Important Role During Various Stages of the Coronavirus Infection Cycle

Overview
Journal J Virol
Date 2010 May 21
PMID 20484504
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

The ubiquitin-proteasome system (UPS) is a key player in regulating the intracellular sorting and degradation of proteins. In this study we investigated the role of the UPS in different steps of the coronavirus (CoV) infection cycle. Inhibition of the proteasome by different chemical compounds (i.e., MG132, epoxomicin, and Velcade) appeared to not only impair entry but also RNA synthesis and subsequent protein expression of different CoVs (i.e., mouse hepatitis virus [MHV], feline infectious peritonitis virus, and severe acute respiratory syndrome CoV). MHV assembly and release were, however, not appreciably affected by these compounds. The inhibitory effect on CoV protein expression did not appear to result from a general inhibition of translation due to induction of a cellular stress response by the inhibitors. Stress-induced phosphorylation of eukaryotic translation initiation factor 2alpha (eIF2alpha) generally results in impaired initiation of protein synthesis, but the sensitivity of MHV infection to proteasome inhibitors was unchanged in cells lacking a phosphorylatable eIF2alpha. MHV infection was affected not only by inhibition of the proteasome but also by interfering with protein ubiquitination. Viral protein expression was reduced in cells expressing a temperature-sensitive ubiquitin-activating enzyme E1 at the restrictive temperature, as well as in cells in which ubiquitin was depleted by using small interfering RNAs. Under these conditions, the susceptibility of the cells to virus infection was, however, not affected, excluding an important role of ubiquitination in virus entry. Our observations reveal an important role of the UPS in multiple steps of the CoV infection cycle and identify the UPS as a potential drug target to modulate the impact of CoV infection.

Citing Articles

Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.

Steigmann J, Zhou X, Suttenberg L, Salman I, Rehmathullah Z, Weinberg J J Virol. 2024; 98(12):e0123824.

PMID: 39508578 PMC: 11650983. DOI: 10.1128/jvi.01238-24.


Pathophysiology of COVID-19-Related Extrapyramidal Disorders.

Cavallieri F, Zedde M, Fioravanti V, Grisanti S, Napoli M, Moratti C Adv Exp Med Biol. 2024; 1457:111-123.

PMID: 39283423 DOI: 10.1007/978-3-031-61939-7_6.


Multiple E3 ligases act as antiviral factors against SARS-CoV-2 via inducing the ubiquitination and degradation of ORF9b.

Yu M, Li J, Gao W, Li Z, Zhang W J Virol. 2024; 98(6):e0162423.

PMID: 38709105 PMC: 11237466. DOI: 10.1128/jvi.01624-23.


Protein Quality Control Systems and ER Stress as Key Players in SARS-CoV-2-Induced Neurodegeneration.

Gavilan E, Medina-Guzman R, Bahatyrevich-Kharitonik B, Ruano D Cells. 2024; 13(2).

PMID: 38247815 PMC: 10814689. DOI: 10.3390/cells13020123.


The Ubiquitin-Proteasome System Facilitates Membrane Fusion and Uncoating during Coronavirus Entry.

Yuan X, Zhang X, Wang H, Mao X, Sun Y, Tan L Viruses. 2023; 15(10).

PMID: 37896778 PMC: 10610886. DOI: 10.3390/v15102001.


References
1.
Tanahashi N, Kawahara H, Murakami Y, Tanaka K . The proteasome-dependent proteolytic system. Mol Biol Rep. 1999; 26(1-2):3-9. DOI: 10.1023/a:1006909522731. View

2.
Krijnse-Locker J, Ericsson M, Rottier P, Griffiths G . Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. J Cell Biol. 1994; 124(1-2):55-70. PMC: 2119890. DOI: 10.1083/jcb.124.1.55. View

3.
Chua P, Lin M, Shih C . Potent inhibition of human Hepatitis B virus replication by a host factor Vps4. Virology. 2006; 354(1):1-6. DOI: 10.1016/j.virol.2006.07.018. View

4.
Crump C, Yates C, Minson T . Herpes simplex virus type 1 cytoplasmic envelopment requires functional Vps4. J Virol. 2007; 81(14):7380-7. PMC: 1933334. DOI: 10.1128/JVI.00222-07. View

5.
Meng L, Mohan R, Kwok B, Elofsson M, Sin N, Crews C . Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999; 96(18):10403-8. PMC: 17900. DOI: 10.1073/pnas.96.18.10403. View